Management of gastrointestinal stromal tumours in the Imatinib era: a surgeon's perspective
Open Access
- 18 July 2008
- journal article
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 6 (1) , 77
Abstract
Surgical resection has remained the mainstay of treatment of GIST with a 5-year-survival of 28–35%. Tyrosine kinase inhibitor (Imatinib) has revolutionised the treatment of these tumours. The current research is directed towards expanding the role of this drug in the treatment of GIST. We present our experience of managing GIST in this institute.Keywords
This publication has 21 references indexed in Scilit:
- Gastrointestinal stromal tumours: Clinical overview, surgery and recent advances in imatinib mesylate therapyEuropean Journal of Surgical Oncology, 2007
- Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST)British Journal of Cancer, 2007
- Pathologic, radiologic and PET scan response of gastrointestinal stromal tumors after neoadjuvant treatment with imatinib mesylateEuropean Journal of Surgical Oncology, 2006
- Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinibInternational Journal of Cancer, 2005
- Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialThe Lancet, 2004
- Is there a role for surgery in patients with “unresectable” cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate?The American Journal of Surgery, 2003
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- Two Hundred Gastrointestinal Stromal TumorsAnnals of Surgery, 2000
- Prognostic Factors Influencing Survival in Gastrointestinal Leiomyosarcomas Implications for Surgical Management and StagingAnnals of Surgery, 1992
- Myosarcomas of the stomach: Natural history, prognostic factors and managementCancer, 1982